|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods<i>:</i></b> Retrospective cohort study in patients with T2DM who initiated GLP-1RAs between 2007 and 2014 in primary health care centers in Catalonia (Spain).
|
31081693 |
2019 |
|
Diabetic Retinopathy
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> GLP-1treatment reduced the levels of NOX3 and SOD2 in DR.
|
29104476 |
2017 |
|
KLEEFSTRA SYNDROME 1
|
0.020 |
Biomarker
|
disease |
BEFREE |
Kleefstra Syndrome (KS) (MIM# 610253) is an autosomal dominant disorder caused by haploinsufficiency of euchromatic histone methyltransferase-1 (<i>EHMT1,</i> GLP).
|
28361100 |
2017 |
|
Kleefstra syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Kleefstra Syndrome (KS) (MIM# 610253) is an autosomal dominant disorder caused by haploinsufficiency of euchromatic histone methyltransferase-1 (<i>EHMT1,</i> GLP).
|
28361100 |
2017 |
|
Nausea
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Nausea was more common with GLP-1RAs than control (53.6% vs. 27.5%, p = 0.002, number-needed-to-harm = 3.8).
|
30187620 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]<sub>95% CI</sub> [ P = .242]; 0.3 [0.1; 0.5]<sub>95% CI</sub> [ P<.001], and 11.8 [3.3; 42.8]<sub>95% CI</sub> [ P<.001] for DUAL II, V, and III, respectively).
|
30383495 |
2019 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
GLP-1RA treatment produced significant reductions relative to baseline in liver histology scores for steatosis (MD, 0.80; 95% CI, 0.49 to 1.11), lobular inflammation (MD, 0.22; 95% CI, 0.00 to 0.45), hepatocellular ballooning (MD, 0.41; 95% CI, 0.15 to 0.67) and fibrosis (MD, 0.35; 95% CI, 0.00 to 0.70).
|
28065744 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1As decreased risks of all-cause and CV mortality and severe hypoglycemia, whereas DPP-4Is had no effect on CV outcomes but increased risks in acute pancreatitis and hypoglycemia.
|
28249585 |
2017 |
|
Nausea
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
GLP-1RAs were well-tolerated, with nausea being the most significant adverse side effect.
|
28276778 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs alone or as titratable fixed-ratio combinations with basal insulin may represent a promising option to advance basal insulin therapy or to initiate injectable therapy in patients with type 2 diabetes inadequately controlled on oral agents.
|
28325801 |
2017 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups.
|
28407414 |
2017 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups.
|
28407414 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
|
28407414 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
|
28407414 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects.
|
29247356 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects.
|
29247356 |
2018 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
GLP-1RAs significantly reduced infarct volume when administered acutely, but not later after stroke.
|
29411931 |
2018 |
|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
GLP-1RAs have also been shown to reduce liver inflammation and fibrosis.
|
30459715 |
2018 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
GLP-1RA ameliorated metabolic memory-induced amyloid-β and tau pathologies in vivo and in vitro.
|
30465895 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RA add-on therapy provides clinically meaningful reductions in HbA1c and postprandial glucose in Asians with T2D inadequately controlled by oral antidiabetic drugs (OADs) or basal insulin ± OADs.
|
30859500 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1RAs are generally well tolerated, with gastrointestinal and injection-site reactions being the most troublesome drug-related adverse events, and are associated with a very low intrinsic risk of hypoglycaemia.
|
31317516 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs may be considered in combination with other glucose-lowering medications because of their ability to lower glucose in a glucose-dependent manner, lowering their risk for hypoglycemia, while improving some cardiorenal risk factors.
|
31318152 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RA reduced major cardiovascular events (MACE) by 13% (HR, 0.87; 95% CI, 0.80-0.96; P = 0.011) with a non-significant heterogeneity between subgroups of patients with and without cardiovascular disease (CVD) (P = 0.220).
|
31373167 |
2019 |
|
Cerebrovascular accident
|
0.060 |
GeneticVariation
|
group |
BEFREE |
GLP-1RA also reduced the risk of cardiovascular death by 12%, of non-fatal stroke by 16%, of hospitalization for heart failure by 9%, of all-cause mortality by 11%, and the broad composite kidney outcome by 17%; the latter appeared to be driven only by a reduction in macroalbuminuria (HR, 0.76 [0.68-0.86]; P = 0.003).
|
31373167 |
2019 |
|
Heart failure
|
0.080 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs have moderate benefits concerning MACE, and also reduce hospitalization for heart failure and all-cause mortality; they also robustly reduce the incidence of macroalbuminuria, without affecting the progression of diabetic renal disease.
|
31373167 |
2019 |